What are the post-operative complications and management strategies for patients with rheumatoid arthritis (RA) undergoing surgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Post-Operative Complications in Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) undergoing surgery have higher rates of complications including infection, dislocation, and readmission compared to patients with osteoarthritis, requiring careful perioperative medication management to minimize these risks. 1

Common Post-Operative Complications in RA Patients

Infection Risk

  • Higher infection rates compared to non-RA patients
  • Prosthetic joint infections are particularly concerning
  • Risk factors include:
    • Disease activity/severity
    • Overall disability
    • Immunosuppressive medications
    • Concurrent chronic diseases (diabetes, hypertension, bronchiectasis, etc.) 2

Other Complications

  • Wound healing problems
  • Dislocation (especially in total hip arthroplasty)
  • Higher readmission rates
  • Disease flares if medications are discontinued inappropriately

Perioperative Management of Antirheumatic Medications

Conventional DMARDs

  • Methotrexate: Continue through surgery
    • Multiple studies show continuation does not increase infection risk 2, 3
    • Stopping methotrexate actually increases risk of complications (15% vs 2%) and disease flares 2
  • Hydroxychloroquine, Sulfasalazine: Continue through surgery
  • Leflunomide: Continue through surgery (despite conflicting data, guidelines recommend continuation due to long half-life)
  • Apremilast: Continue through surgery 1

Biologic Agents

  • Withhold all biologics prior to surgery for one dosing cycle 1
    • Plan surgery after the next dose is due
    • Examples:
      • Adalimumab (every 2 weeks): Schedule surgery in week 3
      • Infliximab (every 8 weeks): Schedule surgery in week 9
      • Rituximab (every 6 months): Schedule surgery during month 7

JAK Inhibitors

  • Withhold tofacitinib for at least 7 days prior to surgery 1
    • Despite short half-life, duration of immunosuppression after discontinuation is not well established

Special Considerations for SLE

  • For severe SLE (lupus nephritis, CNS involvement, etc.):
    • Continue mycophenolate mofetil, azathioprine, cyclosporine, or tacrolimus through surgery 1
    • For belimumab and rituximab: Plan surgery at the end of dosing cycle 1
  • For non-severe SLE:
    • Withhold mycophenolate mofetil, azathioprine, cyclosporine, or tacrolimus 1 week before surgery 1

Glucocorticoids

  • Continue current daily dose of glucocorticoids 1
  • Do NOT use "stress dosing" (supraphysiologic doses) on the day of surgery
  • Attempt to taper to <20 mg/day prednisone equivalent before surgery when possible
  • Higher glucocorticoid exposure increases risk of hyperglycemia and other complications 1

Restarting Medications Post-Surgery

  • Restart biologics approximately 14 days after surgery when: 1

    • Wound shows evidence of healing
    • All sutures/staples are out
    • No significant swelling, erythema, or drainage
    • No clinical evidence of non-surgical site infections
  • Restart conventional DMARDs immediately after surgery (if they were continued) or within 3-5 days if they were withheld

Risk Mitigation Strategies

  1. Optimize disease control before surgery

    • Minimize disease activity to reduce disability-related complications
  2. Minimize glucocorticoid use when possible

    • Consistently associated with increased infection risk 4
    • Taper to lowest effective dose before surgery
  3. Screen for wound healing before restarting biologics

    • Consider visiting nurse services
    • Wound photography for review
    • In-person evaluation for high-risk patients
  4. Monitor for signs of infection

    • Increased pain, erythema, warmth, drainage
    • Systemic symptoms (fever, malaise)
    • Prompt intervention if infection suspected
  5. Balance infection risk against disease flare risk

    • Particularly important in SLE patients where flares may be organ-threatening

Special Considerations for Older RA Patients

  • Higher baseline infection risk
  • More likely to have comorbidities that increase surgical risk
  • May require more careful medication management
  • Consider longer withholding periods for biologics in patients with history of recurrent infections 5

By following these evidence-based guidelines for perioperative medication management, the risk of post-operative complications in RA patients can be significantly reduced while maintaining disease control.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.